To determine whether maternal plasma cell–free DNA sequencing can effectively identify trisomy 18 and 13.
Sixty-two pregnancies with trisomy 18 and 12 with trisomy 13 were selected from a cohort of 4,664 pregnancies along with matched euploid controls (including 212 additional Down syndrome and matched controls already reported), and their samples tested using a laboratory-developed, next-generation sequencing test. Interpretation of the results for chromosome 18 and 13 included adjustment for CG content bias.
Among the 99.1% of samples interpreted (1,971/1,988), observed trisomy 18 and 13 detection rates were 100% (59/59) and 91.7% (11/12) at false-positive rates of 0.28% and 0.97%, respectively. Among the 17 samples without an interpretation, three were trisomy 18. If z-score cutoffs for trisomy 18 and 13 were raised slightly, the overall false-positive rates for the three aneuploidies could be as low as 0.1% (2/1,688) at an overall detection rate of 98.9% (280/283) for common aneuploidies. An independent academic laboratory confirmed performance in a subset.
Among high-risk pregnancies, sequencing circulating cell–free DNA detects nearly all cases of Down syndrome, trisomy 18, and trisomy 13, at a low false-positive rate. This can potentially reduce invasive diagnostic procedures and related fetal losses by 95%. Evidence supports clinical testing for these aneuploidies.
Genet Med 2012:14(3):296–305
clinical validation; detection rate; false-positive rate; fetal DNA; massively parallel shotgun sequencing; prenatal screening; trisomy 18; trisomy 13
At a glance
- The maternal age-specific live birth prevalence of trisomies 13 and 18 compared to trisomy 21 (Down syndrome). Prenat Diagn 2010;30:57–64. .
- http://www.cdc.gov/nchs/data_access/Vitalstatsonline.htm. Accessed November 2011. .
- The risk of fetal loss following a prenatal diagnosis of trisomy 13 or trisomy 18. Am J Med Genet A 2008;146:827–832. .
- Patterns of first-year survival among infants with selected congenital anomalies in Texas, 1995–1997. Teratology 2001;64:267–275. .
- Population-based analyses of mortality in trisomy 13 and trisomy 18. Pediatrics 2003;111: 777–784. .
- Risk-based prenatal screening for trisomy 18 using alpha-fetoprotein, unconjugated oestriol and human chorionic gonadotropin. Prenat Diagn 1995;15:713–723. et al.
- Maternal serum-integrated screening for trisomy 18 using both first- and second-trimester markers. Prenat Diagn 2003;23:243–247. .
- Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10–14 weeks of gestation. Prenat Diagn 1999;19: 1035–1042. .
- Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol 2011;204:205.e1–205.11. ,et al.
- DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 2011;13:913–920. ,et al.
- Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ 2011;342:c7401. ,et al.
- Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc Natl Acad Sci USA 2008;105:20458–20463. ,et al.
- Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc Natl Acad Sci USA 2008;105:16266–16271. .
- Maternal plasma DNA analysis with massively parallel sequencing by ligation for noninvasive prenatal diagnosis of trisomy 21. Clin Chem 2010;56:459–463. ,et al.
- Noninvasive prenatal diagnosis of fetal trisomy 18 and trisomy 13 by maternal plasma DNA sequencing. PLoS ONE 2011;6:e21791. ,et al.
- Personalized copy number and segmental duplication maps using next-generation sequencing. Nat Genet 2009;41:1061–1067. ,et al.
- Surveys 2011, FP-A Maternal Screening 2011. .
- First and second trimester antenatal screening for Down’s syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 2003;10:56–104. .
- Evidence-based obstetric ethics and informed decision-making by pregnant women about invasive diagnosis after first-trimester assessment of risk for trisomy 21. Am J Obstet Gynecol 2005;193:322–326. .
- Prospective intervention trial of a screening protocol to identify fetal trisomy 18 using maternal serum alpha-fetoprotein, unconjugated oestriol, and human chorionic gonadotropin. Prenat Diagn 1992;12:925–930. , .
- Prenatal screening for Down’s syndrome with use of maternal serum markers. N Engl J Med 1992;327:588–593. ,et al.
- Obstet Gynecol 2007;110:1459–1467. .
- Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet 1986;1:1287–1293. .